tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Acne Vulgaris D000152 35 associated lipids
Urination Disorders D014555 9 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Vision Disorders D014786 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Melanoma D008545 69 associated lipids
Hematologic Diseases D006402 3 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Osteoporosis D010024 12 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Kidney Diseases D007674 29 associated lipids
Hematuria D006417 13 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Peterson LB et al. A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus. 1998 Transplantation pmid:9448137
Shivaswamy V et al. Tacrolimus and sirolimus induce reproductive abnormalities in female rats. 2011 Transplantation pmid:21508897
Dumont FJ et al. A tacrolimus-related immunosuppressant with reduced toxicity. 1998 Transplantation pmid:9448138
Miyauchi T et al. Effect of donor-specific splenocytes via portal vein and FK506 in rat small bowel transplantation. 1998 Transplantation pmid:9448139
Charlton M et al. Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation: Results of a Randomized Multicenter Study. 2017 Transplantation pmid:28817434
Rosen HR et al. Significance of early aminotransferase elevation after liver transplantation. 1998 Transplantation pmid:9448146
Mieles L et al. Interaction between FK506 and clotrimazole in a liver transplant recipient. 1991 Transplantation pmid:1721250
Roth D et al. A prospective study of hepatitis C virus infection in renal allograft recipients. 1996 Transplantation pmid:8623154
Koprak S et al. Depletion of the mature CD4+8- thymocyte subset by FK506 analogs correlates with their immunosuppressive and calcineurin inhibitory activities. 1996 Transplantation pmid:8623162
Pirsch JD Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group. 1999 Transplantation pmid:10551653
Singh N et al. Immunosuppressive-associated leukoencephalopathy in organ transplant recipients. 2000 Transplantation pmid:10708096
Zoppo A et al. Trimetazidine counteracts tacrolimus nephrotoxicity in a hypertensive liver transplant patient. 1999 Transplantation pmid:10551656
Haririan A et al. Polyomavirus reactivation in native kidneys of pancreas alone allograft recipients. 2003 Transplantation pmid:12717201
Ciancio G et al. Randomized trial of three induction antibodies in kidney transplantation: long-term results. 2014 Transplantation pmid:24477186
Gonwa T et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. 2003 Transplantation pmid:12717205
Tzakis AG et al. Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation. 2003 Transplantation pmid:12717207
Rush DN et al. Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetil. 2009 Transplantation pmid:19935461
Khanna A et al. Donor bone marrow potentiates the effect of tacrolimus on nonvascularized heart allograft survival: association with microchimerism and growth of donor dendritic cell progenitors from recipient bone marrow. 1998 Transplantation pmid:9500620
Mañez R et al. Fluconazole therapy in transplant recipients receiving FK506. 1994 Transplantation pmid:7515201
Hirano Y et al. Morphological and functional changes of islets of Langerhans in FK506-treated rats. 1992 Transplantation pmid:1373536
Hoffman AL et al. The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. 1990 Transplantation pmid:1690469
Takahara S et al. The in vitro immunosuppressive effect of deoxymethylspergualin in man as compared with FK506 and cyclosporine. 1992 Transplantation pmid:1373537
Johnson MC et al. QT prolongation and Torsades de Pointes after administration of FK506. 1992 Transplantation pmid:1373538
Yasunami Y et al. FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. 1990 Transplantation pmid:1691535
Sindhi R et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. 2001 Transplantation pmid:11571449
Timmermann W et al. Videomicroscopic imaging of graft mucosa for monitoring immunosuppressive therapy after small intestinal transplantation in rats. 1999 Transplantation pmid:10401762
Gupta A et al. Elevated myeloid: plasmacytoid dendritic cell ratio associates with late, but not early, liver rejection in children induced with rabbit anti-human thymocyte globulin. 2009 Transplantation pmid:19696644
Gerlach UA et al. Intragraft and Systemic Immune Parameters Discriminating Between Rejection and Long-Term Graft Function in a Preclinical Model of Intestinal Transplantation. 2017 Transplantation pmid:27607529
Koomans HA and Ligtenberg G Mechanisms and consequences of arterial hypertension after renal transplantation. 2001 Transplantation pmid:11585243
Trimarchi HM et al. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. 1999 Transplantation pmid:10071024
Naesens M et al. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. 2006 Transplantation pmid:17060857
Kaufman DB et al. Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: initial experience in 50 consecutive cases. 1999 Transplantation pmid:10071032
Dominguez J et al. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. 2000 Transplantation pmid:11063349
Conrotto D et al. Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease. 2006 Transplantation pmid:17060865
Khanna A et al. Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells. 1999 Transplantation pmid:10071036
Rostaing L et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. 2005 Transplantation pmid:15818323
Jiang H et al. Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production. 2002 Transplantation pmid:12085006
Grudé P et al. MDR1 gene expression in peripheral blood mononuclear cells after liver transplantation. 2002 Transplantation pmid:12085008
Benigni A et al. The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. 1992 Transplantation pmid:1279848
Mor E et al. Late-onset acute rejection in orthotopic liver transplantation--associated risk factors and outcome. 1992 Transplantation pmid:1279849
Hirano Y et al. The effects of FK506 and cyclosporine on the exocrine function of the rat pancreas. 1992 Transplantation pmid:1279850
Tzakis AG et al. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. 2004 Transplantation pmid:15114087
Stojanovic J et al. Immune Desensitization Allows Pediatric Blood Group Incompatible Kidney Transplantation. 2017 Transplantation pmid:27463537
Bechstein WO et al. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: 1-year results of a large multicenter trial. 2004 Transplantation pmid:15114089
Lo A et al. Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. 2004 Transplantation pmid:15114090
Talbot D et al. Alopecia as a consequence of tacrolimus therapy in renal transplantation? 1997 Transplantation pmid:9415574
Shoker A et al. Heightened CD40 ligand gene expression in peripheral CD4+ T cells from patients with kidney allograft rejection. 2000 Transplantation pmid:10949194
Andoh TF et al. Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. 1994 Transplantation pmid:7509514
Levitsky J et al. Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction. 2011 Transplantation pmid:21239962
Bäckman L et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. 1994 Transplantation pmid:7509516
Hadley S et al. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. 1995 Transplantation pmid:7535482
Alessiani M et al. Combined immunosuppressive therapy with tacrolimus and mycophenolate mofetil for small bowel transplantation in pigs. 1996 Transplantation pmid:8830816
Woodle ES et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. 1996 Transplantation pmid:8830821
Tanaka M et al. Effect of anticomplement agent K76 COOH on hamster-to-rat and guinea pig-to-rat heart xenotransplantation. 1996 Transplantation pmid:8830837
Chan K et al. Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial. 2011 Transplantation pmid:21836540
Gujadhur A et al. CMV sinusitis in a HIV-negative renal transplant recipient. 2014 Transplantation pmid:24827770
Jain AB et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. 1998 Transplantation pmid:9846530
Qi S et al. Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey. 2000 Transplantation pmid:10798741
Borger P et al. Cyclosporine, FK506, mycophenolate mofetil, and prednisolone differentially modulate cytokine gene expression in human airway-derived epithelial cells. 2000 Transplantation pmid:10798763
Riegersperger M et al. Effect of conversion from ciclosporin to tacrolimus on endothelial progenitor cells in stable long-term kidney transplant recipients. 2013 Transplantation pmid:23594858
Poncelet AJ et al. Inhibition of humoral response to allogeneic porcine mesenchymal stem cell with 12 days of tacrolimus. 2008 Transplantation pmid:19077894
Uchida N et al. Mycophenolate and tacrolimus for graft-versus-host disease prophylaxis for elderly after cord blood transplantation: a matched pair comparison with tacrolimus alone. 2011 Transplantation pmid:21677598
Kovarik JM et al. Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients. 2011 Transplantation pmid:21157403
Furlan V et al. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. 1995 Transplantation pmid:7537398
Mañez R et al. Anomalous pattern of IgG antibody response to primary cytomegalovirus infection after solid organ retransplantation. 1995 Transplantation pmid:7537400
Jugie M et al. Study of the impact of liver transplantation on the outcome of intestinal grafts in children. 2006 Transplantation pmid:16612274
Ochiai T et al. Optimal serum trough levels of FK506 in renal allotransplantation of the beagle dog. 1989 Transplantation pmid:2474208
Paty BW et al. Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. 2002 Transplantation pmid:11884930
Dell'Antonio G and Randhawa PS "Striped" pattern of medullary ray fibrosis in allograft biopsies from kidney transplant recipients maintained on tacrolimus. 1999 Transplantation pmid:10030300
Wu MJ et al. Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients. 2011 Transplantation pmid:21912349
Vyas S et al. Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus. 1999 Transplantation pmid:10030303
Song L et al. Effects of ASKP1240 combined with tacrolimus or mycophenolate mofetil on renal allograft survival in Cynomolgus monkeys. 2014 Transplantation pmid:24992357
Baran DA et al. Tacrolimus in cardiac transplantation: efficacy and safety of a novel dosing protocol. 2002 Transplantation pmid:12438960
Kasahara M et al. Role of HLA compatibility in pediatric living-related liver transplantation. 2002 Transplantation pmid:12438966
van Maarseveen EM et al. Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cART: a pilot study. 2013 Transplantation pmid:23250333
Shivaswamy V et al. Metformin improves immunosuppressant induced hyperglycemia and exocrine apoptosis in rats. 2013 Transplantation pmid:23250335
Xu H et al. Simultaneous bone marrow and composite tissue transplantation in rats treated with nonmyeloablative conditioning promotes tolerance. 2013 Transplantation pmid:23250336
Hudnall SD Cardiac hypertrophy postliver transplantation: a role for FK506 and cyclosporine A? 2002 Transplantation pmid:12369583
Ueda M et al. A proposal of FK506 optimal dosing in living related liver transplantations. 1995 Transplantation pmid:7544035
Muthukkumar S et al. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. 1995 Transplantation pmid:7544036
Muraki T et al. Antithrombotic effect of FK506 versus prothrombotic effect of cyclosporine in vivo. 1995 Transplantation pmid:7544038
Stevens C et al. The effects of immunosuppressive agents on in vitro production of human immunoglobulins. 1991 Transplantation pmid:1710843
Metcalfe S and Milner J Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. 1991 Transplantation pmid:1710844
Paolillo JA et al. Posttransplant diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. 2001 Transplantation pmid:11213069
Molmenti EP et al. Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis C viral infection. 2001 Transplantation pmid:11213072
Mourer JS et al. Impact of late calcineurin inhibitor withdrawal on ambulatory blood pressure and carotid intima media thickness in renal transplant recipients. 2013 Transplantation pmid:23715049
Deuse T et al. Significant reduction of acute cardiac allograft rejection by selective janus kinase-1/3 inhibition using R507 and R545. 2012 Transplantation pmid:22971540
Jain A et al. One thousand consecutive primary liver transplants under tacrolimus immunosuppression: a 17- to 20-year longitudinal follow-up. 2011 Transplantation pmid:21378604
Jain AB et al. Capillary blood versus arterial or venous blood for tacrolimus monitoring in liver transplantation. 1995 Transplantation pmid:7545836
Cohen JB et al. Belatacept Compared With Tacrolimus for Kidney Transplantation: A Propensity Score Matched Cohort Study. 2017 Transplantation pmid:27941427
Vincenti F et al. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. 1996 Transplantation pmid:8669100
Uchikoshi F et al. Restoration of immune abnormalities in diabetic BB rats after pancreas transplantation. I. Macrochimerism of donor-graft-derived RT6+ T cells responsible for restoration of immune responsiveness and suppression of autoimmune reaction. 1996 Transplantation pmid:8669109
Lauzurica R et al. Tacrolimus-associated severe bilateral corneal ulcer after renal transplantation. 2002 Transplantation pmid:11923710
Bolley R et al. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort. 2002 Transplantation pmid:11923712
Higgins RM et al. Conversion from tacrolimus to cyclosporin in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. 2000 Transplantation pmid:10919600
Puig I Marí JM et al. Reflex sympathetic dystrophy syndrome of the lower limbs in a renal transplant patient treated with tacrolimus. 2000 Transplantation pmid:10919604
Zieliński A et al. Simultaneous pancreas-kidney transplant from living related donor: a single-center experience. 2003 Transplantation pmid:12923442
Erickson LM et al. Microarray-based gene expression profiles of allograft rejection and immunosuppression in the rat heart transplantation model. 2003 Transplantation pmid:12923448
Maluccio M et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. 2003 Transplantation pmid:12923450
Mayer AD et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. 1997 Transplantation pmid:9275110